Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
Authors:
Open Access
- 17 May 2012
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 13 (1) , 58
Abstract
Background: Pentavalent antimonials (Sb5) and miltefosine are the first-line drugs for treating cutaneous leishmaniasis in Colombia; however, toxicity and treatment duration negatively impact compliance and cost, justifying an active search for better therapeutic options. We compared the efficacy and safety of thermotherapy and m eglumine antimoniate for the treatment of cutaneous leishmaniasis in Colombia. Method: An open randomized Phase III clinical trial was performed in five military health centres. located in northwestern, central and southern Colombia. Volunteers with parasitological positive diagnosis (Giemsa-stained smears) of cutaneous leishmaniasis were included. A single thermotherapy session involving the application of 50°C at the center and active edge of each lesion. Meglumine antimoniate was administered intramuscularly at a dose of 20 mg Sb5/kg weight/day for 20 days. Results: Both groups were comparable. The efficacy of thermotherapy was 64% (86/134 patients) by protocol and 58% (86/149) by intention-to-treat. For the m eglumine antimoniate group, efficacy by protocol was 85% (103/121 patients) and 72% (103/143) by intention-to-treat, The efficacy between the treatments was statistically significant (p 0.01 and Leishmania species responsible for infection. The side effects of m eglumine antimoniate included myalgia, arthralgia, headache and fever. Regarding thermotherapy, the only side effect was pain at the lesion area four days after the initiation of treatment. Conclusion: Although the efficacy rate of m eglumine antimoniate was greater than that of thermotherapy for the treatment of cutaneous leishmaniasis, the side effects were also greater. Those factors, added to the increased costs, the treatment adherence problems and the progressive lack of therapeutic response, make us consider thermotherapy as a first line treatment for cutaneous leishmaniasis. Registered ClinicalTrials.gov NCT00471705Keywords
This publication has 46 references indexed in Scilit:
- Efficacy of Miltefosine for the Treatment of American Cutaneous LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 2010
- A Randomized Controlled Trial of Local Heat Therapy Versus Intravenous Sodium Stibogluconate for the Treatment of Cutaneous Leishmania major InfectionPLOS Neglected Tropical Diseases, 2010
- The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational settingTransactions of the Royal Society of Tropical Medicine and Hygiene, 2009
- Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugsParasitology Research, 2007
- Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica ParasitesPLOS Medicine, 2006
- Advances in leishmaniasisThe Lancet, 2005
- Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic optionsJournal of the American Academy of Dermatology, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- The method used to sample ulcers influences the diagnosis of cutaneous leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2002
- FAILURE OF KETOCONAZOLE TREATMENT IN CUTANEOUS LEISHMANIASISInternational Journal of Dermatology, 1995